Tonix Pharmaceuticals Enrolls First Participant in Military-Related PTSD Phase 3 Trial of FDA Breakthrough Therapy-Designated TNX-102 SL
March 28, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split
March 16, 2017 13:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 16, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program at Oppenheimer’s 27th Annual Healthcare Conference
March 15, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL, a Drug in Phase 3 Development, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-Related PTSD to Begin this Month NEW YORK, March 15, 2017 (GLOBE...
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent Covering Composition and Manufacture of TNX-102 SL
March 14, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 14, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 29th Annual ROTH Conference
March 07, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL, a Phase 3 drug candidate, Recently Granted Breakthrough Therapy Designation by the FDA Pivotal Study in Military-related PTSD to Begin this Quarter NEW YORK, March 07, 2017 (GLOBE...
Tonix Pharmaceuticals Announces Demonstrated Vaccine Activity in First-Ever Synthesized Chimeric Horsepox Virus
March 02, 2017 07:23 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address public health...
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the Cowen and Company 37th Annual Health Care Conference
February 28, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL, a Phase 3 Drug Candidate, Recently Granted Breakthrough Therapy Designation by the US FDA Pivotal Study in Military-Related PTSD to Begin This Quarter NEW YORK, Feb. 28, 2017 (GLOBE...
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at the 2017 BIO CEO & Investor Conference
February 09, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
TNX-102 SL, a Phase 3 drug candidate, Recently Granted Breakthrough Therapy Designation by the FDAPivotal Study in military-related PTSD to Begin this QuarterNEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE)...
Tonix Pharmaceuticals to Present Breakthrough Therapy Designated-PTSD Program and Corporate Update at NobleCon13
January 24, 2017 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
NEW YORK, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), a company that is developing innovative pharmaceutical products to address current and emerging...
Tonix Pharmaceuticals Presented Details of Newly Expanded Product Development Pipeline at 9th Annual Biotech Showcase Conference
January 10, 2017 13:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Development Programs Include Phase 3-Ready Breakthrough Therapy TNX-102 SL, Designed for Bedtime Dosing for PTSD, IND Drug Candidate TNX-601 Designed for Daytime Dosing for PTSD, and Smallpox...